Want to see ACRV full AI Analyst Report?
ACRV Stock Chart & Stats
$2.06
-$0.04(-2.50%)
At close: 4:00 PM EDT
$2.06
-$0.04(-2.50%)
Day’s Range― - ―
52-Week Range$1.27 - $3.56
Previous Close$1.6
Volume150.11K
Average Volume (3M)350.26K
Market Cap
$89.56M
Enterprise Value-$13.37
Total Cash (Recent Filing)$89.96M
Total Debt (Recent Filing)$2.12M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Nov 12, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.88
Shares Outstanding42,853,363
10 Day Avg. Volume440,942
30 Day Avg. Volume350,261
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$10.00Price Target Upside385.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Precision Oncology PlatformA patient-selection platform can improve development efficiency by focusing trials on likely responders. If validated clinically, AP3 may support differentiated oncology programs and improve the probability of advancing targeted therapies.
Low Financial LeverageMinimal debt reduces fixed financial obligations and preserves flexibility while the company funds clinical development. Positive equity provides a stronger capital base than a highly leveraged structure, although continued losses remain a constraint.
Governance And Talent SupportShareholder approval supports continuity of the current strategic direction and provides stock-based incentives to compete for specialized biotechnology talent. Retaining scientific and clinical employees is important for advancing programs through development.
Bears Say
Pre-Revenue Business ModelA lack of commercial revenue leaves the company dependent on financing and clinical milestones rather than operating cash inflows. This limits operating leverage and makes future value highly dependent on successful development and commercialization.
Persistent Cash BurnSustained negative operating and free cash flow consumes resources needed for clinical programs. The decline in assets and equity indicates that losses are eroding financial capacity, increasing the likelihood of future capital needs.
Equity Dilution RiskThe enlarged equity incentive pool may dilute existing holders over time, particularly while the company has no revenue and relies on external capital. Annual share increases can compound dilution if stock compensation remains a primary funding tool.
Acrivon Therapeutics, Inc. News
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $1.27 and its highest was $3.56 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $89.56M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 71 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Aug 12, 2026. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.502 by $0.072.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.45.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 42,853,363 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.502. Following the earnings report the stock price went up 7.558%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrivon Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (385.44% Upside)
$10.00 (385.44% Upside)
Blogger Sentiment
Bullish
ACRV Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
ACRV Stock 12 Month Forecast
Average Price Target
$10.00
▲(385.44% Upside)
Technical Analysis
Medicinova
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
35.74% Insiders
2.57% Mutual Funds
34.95% Other Institutional Investors
24.25% Public Companies and
Individual Investors